pomalidomide has been researched along with Disease Exacerbation in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernardini, R; Burgaletto, C; Cantarella, G; Carboni, E; Cardia, MC; Carta, AR; Casu, MA; Coroneo, V; De Simone, A; Ena, A; Etzi, M; Fusco, G; Greig, NH; Lai, F; Palmas, MF; Picci, L; Pisanu, A; Scerba, MT; Tweedie, D | 1 |
| Benettaib, B; Kassir, N; Li, Y; Ogasawara, K; Palmisano, M; Wang, X; Zhou, S | 1 |
| Ambinder, R; Cheever, M; Ekwede, I; George, J; Goncalves, PH; Gulley, JL; Lurain, K; Mangusan, R; Ramaswami, R; Uldrick, TS; Wang, HW; Widell, A; Yarchoan, R | 1 |
| Campioni, M; DeCosta, L; Fink, L; Flinois, A; Gazzola, C; Gonzalez-McQuire, S; Leleu, H; Mennini, FS; Schoen, P; Yong, K | 1 |
| Gourd, E | 1 |
| Scott, LJ | 1 |
| Lonial, S; Usmani, SZ | 1 |
| Camarero, J; Flores, B; Gisselbrecht, C; Hanaizi, Z; Hemmings, R; Laane, E; Pignatti, F; Salmonson, T; Sancho-Lopez, A | 1 |
| Amatya, R; Belch, A; Dimopoulos, M; Gibson, CJ; Jacques, C; Moreau, P; Palumbo, A; San Miguel, J; Schey, S; Song, KW; Sonneveld, P; Sternas, L; Weisel, K; Yu, X; Zaki, M | 1 |
| Abouzaid, S; Chen, CC; Hussein, M; McGuiness, CB; Parikh, K; Purnomo, L; Wade, RL | 1 |
| Allred, JB; Bergsagel, PL; Buadi, F; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, K; Lust, JA; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Roy, V; Russell, SJ; Short, KD; Stewart, AK; Zeldenrust, S | 1 |
| Abdel-Wahab, O; Barbui, T; Barosi, G; Bernard, OA; Bhalla, K; Cazzola, M; Crispino, JD; Finazzi, G; Gisslinger, H; Gotlib, J; Guglielmelli, P; Gupta, V; Hoffman, R; Kiladjian, JJ; Kralovics, R; Mughal, T; Noel, P; Odenike, O; Pardanani, A; Tefferi, A; Thiele, J; Van Etten, RA; Vannucchi, AM | 1 |
3 review(s) available for pomalidomide and Disease Exacerbation
| Article | Year |
|---|---|
Pomalidomide: a review of its use in patients with recurrent multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Multiple Myeloma; Recurrence; Survival Rate; Thalidomide | 2014 |
Novel drug combinations for the management of relapsed/refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Disease Management; Disease Progression; Histone Deacetylase Inhibitors; Humans; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Recurrence; Thalidomide | 2014 |
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Europe; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Survival Rate; Thalidomide | 2015 |
1 trial(s) available for pomalidomide and Disease Exacerbation
| Article | Year |
|---|---|
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Quality of Life; Thalidomide | 2015 |
8 other study(ies) available for pomalidomide and Disease Exacerbation
| Article | Year |
|---|---|
Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Cytokines; Disease Models, Animal; Disease Progression; Drug Repositioning; Humans; Microglia; Neuroprotective Agents; Parkinson Disease; Rats; Substantia Nigra; Thalidomide; Tumor Necrosis Factor-alpha | 2022 |
Recurrent or progressive pediatric brain tumors: population pharmacokinetics and exposure-response analysis of pomalidomide.
Topics: Adolescent; Antineoplastic Agents, Immunological; Brain Neoplasms; Child; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Male; Neoplasm Recurrence, Local; Thalidomide; Young Adult | 2021 |
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; HIV Infections; Humans; Immune Checkpoint Inhibitors; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Male; Middle Aged; Progression-Free Survival; Retrospective Studies; Thalidomide; Time Factors | 2021 |
Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Female; France; Health Expenditures; Health Resources; Hospitalization; Humans; Italy; Lenalidomide; Male; Middle Aged; Models, Econometric; Multiple Myeloma; Retrospective Studies; Thalidomide; United Kingdom | 2018 |
Combination therapy for first relapse of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Dexamethasone; Disease Progression; Humans; Multicenter Studies as Topic; Multiple Myeloma; Recurrence; Remission Induction; Stem Cell Transplantation; Thalidomide; Time Factors; Treatment Outcome | 2018 |
Real-World Treatment Patterns, Time to Next Treatment, and Economic Outcomes in Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide or Carfilzomib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Costs and Cost Analysis; Dexamethasone; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Retrospective Studies; Thalidomide | 2017 |
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Drug Tolerance; Female; Humans; Male; Middle Aged; Multiple Myeloma; Risk Assessment; Survival Rate; Thalidomide | 2010 |
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.
Topics: Clinical Trials as Topic; Disease Progression; DNA Methylation; DNA, Neoplasm; Drugs, Investigational; Genes, Neoplasm; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Histone Deacetylase Inhibitors; Humans; Inflammation; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Myeloproliferative Disorders; Neoplasm Proteins; Polyethylene Glycols; Prognosis; Recombinant Proteins; Thalidomide; Treatment Outcome | 2012 |